Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Perigon Wealth Management LLC

Perigon Wealth Management LLC lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 18.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,802 shares of the medical research company’s stock after selling 854 shares during the quarter. Perigon Wealth Management LLC’s holdings in Edwards Lifesciences were worth $290,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EW. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth $25,000. Compass Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $31,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $34,000. Jackson Grant Investment Advisers Inc. purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $38,000. Finally, Janiczek Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 108.6% during the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after buying an additional 303 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. Evercore ISI upped their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Citigroup upped their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the sale, the director now owns 4,486 shares of the company’s stock, valued at $414,596.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the sale, the chief financial officer now directly owns 19,074 shares in the company, valued at approximately $1,809,931.86. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 over the last 90 days. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Trading Up 1.0 %

NYSE EW opened at $90.06 on Wednesday. The firm’s 50-day moving average is $90.11 and its two-hundred day moving average is $78.07. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. The stock has a market capitalization of $54.21 billion, a P/E ratio of 39.16, a PEG ratio of 4.47 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the company posted $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.